Kane Biotech Inc. (CVE:KNE – Get Free Report) shares dropped 33.3% during trading on Monday . The company traded as low as C$0.02 and last traded at C$0.02. Approximately 1,391,150 shares were traded during trading, an increase of 759% from the average daily volume of 161,896 shares. The stock had previously closed at C$0.03.
Kane Biotech Trading Down 33.3%
The company has a quick ratio of 0.39, a current ratio of 0.45 and a debt-to-equity ratio of -135.17. The firm has a 50 day moving average price of C$0.03 and a 200 day moving average price of C$0.03. The stock has a market capitalization of C$4.10 million, a PE ratio of -2.00 and a beta of 1.05.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
